BridgeBio Q3 Revenue Triples to $353.2M; Three PDUFA Dates in Seven Months
BBIO sits 19% above its 52-week low of $60.22 on elevated volume (1.9× avg).
Summary
BridgeBio reported Q3 2026 revenue of $353.2M, up from $120.7M a year ago, and cut its operating loss to $11.6M while holding $1.5 billion in cash. Three Priority Review PDUFA dates land within seven months, starting with BBP-418 on November 27, 2026.
Key Events · Earnings and Guidance · BBIO
-
Q3 Revenue Triples to $353.2M
Total revenues, net were $353.2 million versus $120.7 million a year ago, driven by $253.2 million of U.S. Attruby net product revenue (up about $145 million year over year) and $79.3 million of license and services revenue.
-
Operating Loss Narrows to $11.6M
Loss from operations fell to $11.6 million from $145.2 million, helped by a one-time $75.0 million BEYONTTRA sales milestone from Bayer. Net loss attributable to common stockholders was $83.0 million, or $0.42 per share.
-
$1.5B Cash Funds Three Launches
Cash, cash equivalents and marketable securities totaled $1.5 billion at September 30, 2026, up from $587.5 million at year-end 2025, which the company says fully funds all three launches and expansion indications.
-
Three PDUFA Dates in Seven Months
BBP-418 for LGMD2I/R9 has a November 27, 2026 PDUFA date, oral infigratinib for achondroplasia February 4, 2027, and encaleret for ADH1 May 8, 2027 — all under Priority Review, with U.S. field teams staffed for each.
Analysis · BBIO · Life Sciences
The commercial business is now close to covering its own costs: revenue more than doubled year over year and the operating loss shrank to $11.6M from $145.2M. With $1.5 billion in cash, BridgeBio says it can fund all three launches without raising more money. Regulatory catalysts are the bigger swing factor. BBP-418 has a November 27, 2026 PDUFA date, infigratinib February 4, 2027 and encaleret May 8, 2027, each a potential first-in-class approval for a disease with no approved therapy. Any one approval changes the revenue base; a complete response letter on BBP-418, now about a month away, would hit the stock hardest.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BBIO was trading at $71.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.8B. The 52-week trading range was $60.22 to $93.42. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.